American Marconi Wireless News - Telomir Pharmaceuticals Announces Breakthrough Results With Telomir-1 Fully Reversing Oxidative Stress in Human Cell Lines and Exploring Potential as a Treatment for Avian Influenza (Bird Flu) and Other Viruses

MIAMI, FLORIDA / ACCESS Newswire / January 28, 2025 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), or Telomir, a leader in age-reversal science, today announced groundbreaking results from its recent preclinical studies conducted in human cell lines. These studies demonstrated the ability of Telomir-1 to fully reverse copper-induced elevation of Reactive Oxygen Species (ROS) and provide robust cellular protection against copper toxicity.

"The results of our studies demonstrate the exceptional potential of Telomir-1 in addressing oxidative stress and its related pathologies," said Raphael Mayer, Ph.D., Founder and CEO of Smart Assays Biotechnologies Ltd. "Telomir-1's ability to fully normalize copper-induced ROS and to protect the cells from damage represents a significant leap forward in our understanding of this compound's therapeutic potential."

Oxidative stress occurs when there is an imbalance between free radicals and antioxidants in the body. This imbalance leads to the generation of harmful ROS, which can damage cellular structures, including DNA, mitochondria, proteins, and lipids. It plays a central role in the progression of diseases such as Alzheimer's, AMD, cancer, cardiovascular conditions, and diabetes. Furthermore, oxidative stress accelerates telomere shortening, compromising cellular repair mechanisms and contributing to aging and disease development.

In the context of viral infections, such as avian influenza (bird flu), oxidative stress is a key factor in disease severity. Viral infections trigger and exploit excessive ROS production as a mode to facilitate their replication, leading to widespread inflammation, cellular damage, and impaired immune responses. This oxidative damage exacerbates disease progression and increases the risk of severe outcomes. Addressing oxidative stress in viral infections is critical for mitigating these effects and improving patient recovery.

Telomir-1's potential ability to shield cells from copper toxicity is particularly significant in diseases linked to copper dysregulation. Conditions such as Wilson's disease, AMD, and Alzheimer's disease are directly affected by excess copper, which exacerbates oxidative stress and cellular damage. By mitigating copper toxicity, Telomir-1 offers a targeted approach to protecting cellular health and addressing the root causes of these debilitating diseases.

Erez Aminov, Chairman and CEO of Telomir, added, "With its unique regulatory mechanism and broad application, Telomir-1 is more than a single treatment-it is a platform that could potentially transform healthcare for millions. In addition to addressing age-related diseases, we are exploring its role in combating oxidative stress in viral infections such as avian influenza (bird flu). The urgent need for effective treatments underscores the importance of Telomir-1 in reducing the severe effects of oxidative stress during outbreaks. Our mission is to leverage its capabilities to address unmet medical needs and improve patient outcomes worldwide.

Key findings from the study include:

• Reversal of Oxidative Stress: Telomir-1 has potential to fully normalize ROS levels, effectively reversing oxidative damage in human cell lines.

• Cellular Protection: Telomir-1 provided strong protection against copper-induced toxicity while maintaining cellular integrity.

• Regulatory Mechanism: Telomir-1 demonstrated effects at doses significantly lower than copper levels, indicating its unique regulatory mechanism beyond copper ion chelation.

Dr. Itzchak Angel, Chief Scientific Advisor at Telomir, commented, "These findings underscore the unique profile of Telomir-1 as an intracellular regulator of oxidative stress. Its ability to act at low doses, rather than as a chelator, to reverse copper-induced ROS and toxicity positions it as a promising candidate for multiple indications, including neurodegeneration and metabolic disorders."

Transformative Potential for Wilson's Disease, Alzheimer's, AMD, Cancer, and Cardiovascular Diseases

• Wilson's Disease: A rare genetic disorder caused by excessive copper accumulation, affecting approximately 1 in 30,000 people globally. Current treatments come with severe side effects, but Telomir-1's ability to regulate copper metabolism and normalize ROS presents a promising alternative to address the root causes of the disease while minimizing adverse effects.

• Alzheimer's Disease: Oxidative stress, particularly the one associated with copper, contributes to neurodegeneration, protein misfolding and aggregation, and subsequent cognitive decline. By reversing the oxidative damage, Telomir-1 offers the potential to slow or halt disease progression and improve patient outcomes.

• Age-related Macular Degeneration (AMD): Oxidative stress is a major driver of retinal damage and vision loss in AMD. Telomir-1's protective effects on cells could provide a novel approach to preserving vision and addressing the underlying causes of this condition.

• Cancer: Oxidative stress fuels DNA damage, tumor growth, and resistance to treatments like chemotherapy. Telomir-1's ability to reverse ROS damage positions it as a potential adjunct to improve cancer therapies and patient survival rates.

• Cardiovascular Diseases: Oxidative stress impairs vascular function, accelerates atherosclerosis, ischemic conditions, and exacerbates chronic inflammation. Telomir-1's regulatory effects could protect cardiovascular health and reduce the risk of these conditions.

Telomir-1's ability to reverse oxidative damage and protect cells highlights its transformative potential across these diseases, offering innovative solutions to improve patient care.

Future Exploration: Oxidative Stress and Viruses, Including Avian Influenza (Bird Flu)

Telomir is also exploring the application of Telomir-1 as an oral treatment for oxidative stress caused by viral infections, including emerging threats such as avian influenza (bird flu). The bird flu has infected over 868 people globally as of 2023, with a mortality rate of approximately 50%, according to the World Health Organization (WHO). Recent adaptations of the virus for human transmission have raised significant public health concerns. The U.S. government has allocated significant funding, exceeding $1 billion, to accelerate the development of effective therapies for viral outbreaks like bird flu.

This zoonotic virus is characterized by severe inflammation and elevated oxidative stress, both of which contribute to rapid disease progression and organ damage. Currently, there are no approved drugs specifically targeting the oxidative stress caused by the bird flu or similar viruses. Telomir-1's ability to reverse oxidative stress and protect cells offers a promising avenue for addressing this gap. By mitigating the cellular damage associated with oxidative stress, Telomir-1 has the potential to play a critical role in reducing the severity of such infections. This represents a key area of future investigation for Telomir.

About Telomir Pharmaceuticals, Inc.

Telomir Pharmaceuticals, Inc. (Nasdaq:TELO) is a pre-clinical stage pharmaceutical company seeking to lead development in several areas, including age-reversal science. Telomir is focused on the development of Telomir-1, a novel small molecule metal ion regulator designed to lengthen the DNA's protective telomere caps, which are crucial in the aging process. Telomir's goal is to explore the potential of Telomir-1 starting with ongoing research in animals and then in humans.

Telomeres are the protective end caps of a chromosome made up of DNA sequences and proteins. As humans age, telomeres shorten, with metal reactivity accelerating the process, which presents humans and pet animals with an increased chance of contracting a number of degenerative and age-related diseases. Telomir's goal is to develop and gain regulatory approval for Telomir-1, proposed to be dosed orally, with the broader aim of promoting longevity and enhancing overall quality of life.

Telomir-1 is in preclinical development and has not yet been tested in humans. There is no assurance that Telomir-1 will proceed through development or will ultimately receive FDA approval for marketing.

Cautionary Note Regarding Forward-Looking Statements

This press release, statements of Telomir Pharmaceuticals' management or advisors related thereto, and the statements contained in the news story linked in this release contain "forward-looking statements," which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," "seeks," "will," and variations of these words or similar expressions that are intended to identify forward-looking statements. Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements.

These risks and uncertainties include, but are not limited to, the potential use of the data from our studies, our ability to develop and commercialize Telomir-1 for specific indications, and the safety of Telomir-1.

View the original press release on ACCESS Newswire

Y.Kobayashi--AMWN